Literature DB >> 8302597

Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation.

H Lovec1, A Sewing, F C Lucibello, R Müller, T Möröy.   

Abstract

Circumstantial evidence implicates the putative cell cycle regulator cyclin D1 in the process of malignant transformation. Overexpression of cyclin D1 is observed in mammary carcinomas as a result of gene amplification and in parathyroid adenomas and centrocytic B-cell lymphomas as a consequence of chromosomal rearrangements and juxtaposition of the cyclin D1 gene to strong transcriptional control elements. These findings suggest that deregulation of cyclin D1 expression may contribute to malignant transformation in these tumours. To date, however, an oncogenic potential of cyclin D1 has not been demonstrated and the mechanism of its oncogenic activation remains obscure although overexpression of the wild-type protein is likely. We report here that the overexpression of cyclin D1 induces transformation in primary rat embryo fibroblasts in cooperation with activated Ha-ras. Cyclin D1/Ha-ras transformed cells are immortalized, show anchorage independence and give rise to fibrosarcomas in nude mice. Our data directly demonstrate that cyclin D1 is a proto-oncogene that can be activated by transcriptional deregulation. Its previously demonstrated ability to interact with putative cell cycle regulators suggests that cyclin D1 defines a new class of proto-oncogenes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8302597

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  56 in total

1.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.

Authors:  E Neuman; M H Ladha; N Lin; T M Upton; S J Miller; J DiRenzo; R G Pestell; P W Hinds; S F Dowdy; M Brown; M E Ewen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway.

Authors:  Janet L Maldonado; Luika Timmerman; Jane Fridlyand; Boris C Bastian
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

3.  Amplification and overexpression of the cyclin D1 gene in head and neck squamous cell carcinoma.

Authors:  X Wang; Z P Pavelic; Y Q Li; L Wang; L Gleich; K Radack; J L Gluckman; P J Stambrook
Journal:  Clin Mol Pathol       Date:  1995-10

4.  Regulation of cyclin D1 RNA stability by SNIP1.

Authors:  Cameron P Bracken; Steven J Wall; Benjamin Barré; Kostya I Panov; Paul M Ajuh; Neil D Perkins
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

5.  Effects of matrine on proliferation and apoptosis of cultured retinoblastoma cells.

Authors:  Bowen Zhao; Bin Li; Shuwei Bai; Ling Shen; Ruojin Ren; Jost B Jonas; Xiaolin Xu; Qingjun Lu; Qian Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-25       Impact factor: 3.117

6.  A better cell cycle target for gene therapy of colorectal cancer: cyclin G.

Authors:  Rodrigo Perez; Nancy Wu; Adam A Klipfel; Robert W Beart
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

7.  Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression.

Authors:  H Jiang; H S Chou; L Zhu
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site.

Authors:  A Schulze; K Zerfass; D Spitkovsky; S Middendorp; J Bergès; K Helin; P Jansen-Dürr; B Henglein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Krüppel-like factor 5 promotes mitosis by activating the cyclin B1/Cdc2 complex during oncogenic Ras-mediated transformation.

Authors:  Mandayam O Nandan; Sengthong Chanchevalap; W Brian Dalton; Vincent W Yang
Journal:  FEBS Lett       Date:  2005-08-29       Impact factor: 4.124

10.  Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.

Authors:  Jae Young So; Hong Jin Lee; Pavel Kramata; Audrey Minden; Nanjoo Suh
Journal:  Mol Cell Pharmacol       Date:  2012-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.